Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Nanda Horeweg"'
Autor:
Anne Sophie V.M. Van den Heerik, Natalja T. Ter Haar, Lisa Vermij, Jan J. Jobsen, Mariel Brinkhuis, Suzan M. Roothaan, Alicia Leon-Castillo, Gitte Ortoft, Estrid Hogdall, Claus Hogdall, Tom Van Wezel, Ludy C.H.W. Lutgens, Marie A.D. Haverkort, Jas Khattra, Jessica N. McAlpine, Carien L. Creutzberg, Vincent T.H.B.M. Smit, C. Blake Gilks, Nanda Horeweg, Tjalling Bosse
Publikováno v:
JCO Global Oncology, Vol , Iss 9 (2023)
PURPOSEDetection of 11 pathogenic variants in the POLE gene in endometrial cancer (EC) is critically important to identify women with a good prognosis and reduce overtreatment. Currently, POLE status is determined by DNA sequencing, which can be expe
Externí odkaz:
https://doaj.org/article/fba14e34232b4bcea6998f7113f0afe7
Autor:
Nanda Horeweg, Hagma H. Workel, Dominik Loiero, David N. Church, Lisa Vermij, Alicia Léon-Castillo, Ricki T. Krog, Stephanie M. de Boer, Remi A. Nout, Melanie E. Powell, Linda R. Mileshkin, Helen MacKay, Alexandra Leary, Naveena Singh, Ina M. Jürgenliemk-Schulz, Vincent T. H. B. M. Smit, Carien L. Creutzberg, Viktor H. Koelzer, Hans W. Nijman, Tjalling Bosse, Marco de Bruyn, TransPORTEC consortium
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-10 (2022)
Tertiary lymphoid structures (TLS) are associated with a reduced risk of cancer recurrence and improved response to immune checkpoint blockade in several tumor types. Here the authors identify L1CAM as a marker for mature TLS and show that the presen
Externí odkaz:
https://doaj.org/article/6cc5d5b840f843b2b959b31b5c279a0f
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Endometrial cancer (EC) diagnostics is evolving into a system in which molecular aspects are increasingly important. The traditional histological subtype-driven classification has shifted to a molecular-based classification that stratifies EC into DN
Externí odkaz:
https://doaj.org/article/1b018f63aa4f43d69bc08d0cb65b3b54
Autor:
Marina Marinkovic, Lennart J. Pors, Vincent van den Berg, Femke P. Peters, Ann Schalenbourg, Leonidas Zografos, Alessia Pica, Jan Hrbacek, Sjoerd G. Van Duinen, T. H. Khanh Vu, Jaco C. Bleeker, Coen R. N. Rasch, Martine J. Jager, Gregorius P. M. Luyten, Nanda Horeweg
Publikováno v:
Cancers, Vol 13, Iss 24, p 6241 (2021)
Objective: To assess oncological and ophthalmological outcomes after international referral of uveal melanoma patients for proton therapy. Materials and Methods: This is a retrospective study among Dutch uveal melanoma patients who were treated in Sw
Externí odkaz:
https://doaj.org/article/f77aad3aa0f947bd8fef023d486bb1fb
Autor:
Anouk Corbeau, Remi A. Nout, Jan Willem M. Mens, Nanda Horeweg, Jérémy Godart, Ellen M. Kerkhof, Sander C. Kuipers, Mariette I. E. van Poelgeest, Judith R. Kroep, Ingrid A. Boere, Helena C. van Doorn, Mischa S. Hoogeman, Uulke A. van der Heide, Hein Putter, Marij J. P. Welters, Sjoerd H. van der Burg, Carien L. Creutzberg, Stephanie M. de Boer
Publikováno v:
Cancers, Vol 13, Iss 20, p 5179 (2021)
External beam radiation therapy (EBRT) with concurrent chemotherapy followed by brachytherapy is a very effective treatment for locally advanced cervical cancer (LACC). However, treatment-related toxicity is common and reduces the patient’s quality
Externí odkaz:
https://doaj.org/article/d341305a04fe4fd289b98eefee29523e
Autor:
Nanda Horeweg, Prachi Mittal, Patrycja L. Gradowska, Ingrid Boere, Supriya Chopra, Remi A. Nout
Publikováno v:
Cancers, Vol 13, Iss 8, p 1880 (2021)
Background: Standard of care for locally advanced cervical cancer is chemoradiation and brachytherapy. The addition of adjuvant systemic treatment may improve overall survival. A systematic review and meta-analysis was conducted to summarize evidence
Externí odkaz:
https://doaj.org/article/a6e4107c89674f528085da7b003ef573
Autor:
Lisa Vermij, Nanda Horeweg, Alicia Leon-Castillo, Tessa A. Rutten, Linda R. Mileshkin, Helen J. Mackay, Alexandra Leary, Melanie E. Powell, Naveena Singh, Emma J. Crosbie, Vincent T.H.B.M. Smit, Carien L. Creutzberg, Tjalling Bosse
Publikováno v:
Cancers, Vol 13, Iss 1, p 44 (2020)
HER2 status has not been investigated in the context of the molecular endometrial cancer (EC) classification. Here, we aimed to determine the clinicopathological features and prognostic significance of the HER2 status in the molecularly classified PO
Externí odkaz:
https://doaj.org/article/67bd53df863848ecb637a91fc607a341
Autor:
Sarah Fremond, Sonali Andani, Jurriaan Barkey Wolf, Jouke Dijkstra, Sinéad Melsbach, Jan J Jobsen, Mariel Brinkhuis, Suzan Roothaan, Ina Jurgenliemk-Schulz, Ludy C H W Lutgens, Remi A Nout, Elzbieta M van der Steen-Banasik, Stephanie M de Boer, Melanie E Powell, Naveena Singh, Linda R Mileshkin, Helen J Mackay, Alexandra Leary, Hans W Nijman, Vincent T H B M Smit, Carien L Creutzberg, Nanda Horeweg, Viktor H Koelzer, Tjalling Bosse
Publikováno v:
The Lancet Digital Health, 5(2), e71-e82. Lancet Publishing Group
The Lancet Digital Health, 5(2), e71-e82. Elsevier
The Lancet Digital Health, 5(2), e71-e82. Elsevier Ltd.
The Lancet Digital Health, 5(2), e71-e82. Elsevier
The Lancet Digital Health, 5(2), e71-e82. Elsevier Ltd.
Background: Endometrial cancer can be molecularly classified into POLEmut, mismatch repair deficient (MMRd), p53 abnormal (p53abn), and no specific molecular profile (NSMP) subgroups. We aimed to develop an interpretable deep learning pipeline for wh
Autor:
David N. Church, Viktor H. Koelzer, Hans W. Nijman, Tjalling Bosse, Carien L. Creutzberg, Vincent T. Smit, Elzbieta M. van der Steen-Banasik, Jan J. Jobsen, Ludy C.H.W. Lutgens, Ina M. Jürgenliemk-Schulz, Michelle Osse, Kirsten D. Mertz, Annechien Plat, Alicia León-Castillo, Katarzyna Kedzierska, Ellen Stelloo, Remi A. Nout, Marco de Bruyn, Nanda Horeweg
Supplementary Tables 1-14 and Supplementary Figures 1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::053d0ebe34ebd8afd1aefeb61f40f9a1
https://doi.org/10.1158/2326-6066.22543677.v1
https://doi.org/10.1158/2326-6066.22543677.v1
Autor:
David N. Church, Viktor H. Koelzer, Hans W. Nijman, Tjalling Bosse, Carien L. Creutzberg, Vincent T. Smit, Elzbieta M. van der Steen-Banasik, Jan J. Jobsen, Ludy C.H.W. Lutgens, Ina M. Jürgenliemk-Schulz, Michelle Osse, Kirsten D. Mertz, Annechien Plat, Alicia León-Castillo, Katarzyna Kedzierska, Ellen Stelloo, Remi A. Nout, Marco de Bruyn, Nanda Horeweg
Optimum risk stratification in early-stage endometrial cancer combines clinicopathologic factors and the molecular endometrial cancer classification defined by The Cancer Genome Atlas (TCGA). It is unclear whether analysis of intratumoral immune infi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::598b00a1fe1b6386eaf503615b4db1bd
https://doi.org/10.1158/2326-6066.c.6550359
https://doi.org/10.1158/2326-6066.c.6550359